Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide, with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor, FGFR4, in hepatocarcinogenesis, dependence of human cancer on FGFR4 has not been demonstrated. Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in HCC patients with aberrant FGF19 expression. Mutations were identified in the gatekeeper and hinge-1 residues in the kinase domain of FGFR4 upon disease progression in 2 patients treated with fisogatinib, which were confirmed to mediate resistance in vitro and in vivo. A gatekeeper-agnostic, pan-FGFR inhibitor decreased HCC xenograft growth in the presence of these mutations, demonstrating continued FGF19-FGFR4 pathway dependence. These results validate FGFR4 as an oncogenic driver and warrant further therapeutic targeting of this kinase in the clinic.
INTRODUCTION
Inhibitors of oncogenic driver kinases have significantly improved treatment of many cancers over the past 2 decades. Drugs targeting BCR/ABL, BRAF, EGFR, ALK, and HER2 have dramatically increased therapeutic responses in patients harboring these activated kinases (1).
While the activity of targeted compounds across various cancers has aided the elucidation of key oncogenic dependencies, the acquisition of on-target resistance mutations has irrefutably validated disease drivers. From this perspective, resistance to targeted therapies is a doubleedged sword that provides biological insights while curbing clinical benefit (1,2).
Identifying and characterizing the mechanisms of acquired resistance is crucial to improving patient care and validating drivers of disease to gain the most value from targeted therapies and improve patient outcomes. The success of next-generation therapies substantiates this approach. Osimertinib has been approved to treat non-small-cell lung cancers that are resistant to gefitinib and erlotinib via a gatekeeper mutation, T790M (3) . Avapritinib received Breakthrough Therapy Designation for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumors harboring PDGFRα D842V, which confers resistance to imatinib (4) . These examples underscore that despite the presence of resistance, cancers can remain longitudinally addicted to a driver oncogene, and significant benefit can be derived from targeted therapies with unique binding modes that circumvent target resistance mutations.
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide (5) with no targeted therapies, as the oncogenic drivers of HCC remain unvalidated. Currently, the multikinase inhibitors sorafenib and lenvatinib are approved in the first-line setting, and nivolumab, regorafenib and cabozantinib have recently been approved as second-line therapies; however, these drugs increase median survival only by a few months, and the identification of primary and acquired resistance mechanisms has been elusive (6) (7) (8) (9) (10) . Potential drivers of HCC have been identified through genomic profiling, and FGF19 amplification has been uncovered as an aberrant event in some patients. The FGF19 receptor, FGFR4, and its coreceptor, klotho-β (KLB), are abundantly expressed in normal liver, whereas FGF19 is normally expressed by the ileum upon stimulation by bile acids to repress bile acid production by the liver (11) . FGF19 also activates MAPK signaling and induces hepatocyte proliferation crucial for liver repair and regeneration (12) . In HCC tumors that overexpress FGF19, constitutive signaling through FGFR4 can lead to unchecked proliferation and neoplastic progression (13, 14) , and accordingly, antibody-or small molecule-mediated inhibition of FGFR4 reduces tumor growth in liver cancer models (15, 16) . These findings, coupled with the fact that FGF19 amplification is associated with a poor prognosis (17) , nominate the FGF19 pathway as a driver of disease in HCC and FGFR4 as a potential therapeutic target.
Fisogatinib (BLU-554) is a potent and selective, type I irreversible inhibitor of FGFR4 that has been evaluated in a first-in-human, phase 1 study in patients with advanced HCC (NCT02508467). fisogatinib is well tolerated, and preliminary clinical activity suggested that FGF19 overexpression predicts response to fisogatinib treatment (18) , validating FGF19-FGFR4 pathway activation as a driver of disease. Given its kinome selectivity and clinical response rate, fisogatinib is the first targeted investigational agent that can also be used to determine whether on-target mutations in FGFR4 mediate treatment resistance, further validating the driver status of FGF19-FGFR4 pathway activation. In this study, we describe mutations in the gatekeeper (V550) and hinge-1 (C552) residues of FGFR4 that confer resistance to fisogatinib in the clinical setting, and we validate those mechanisms of resistance in vivo and in vitro. This study further demonstrates continued FGF19-FGFR4 pathway dependency by showing that a gatekeeper-agnostic, pan-FGFR inhibitor can be active against FGFR4 V550M tumors in vivo.
RESULTS

Clinical Identification of Fisogatinib Resistance Mutations in FGFR4
To establish whether acquired FGFR4 mutations contributed to progressive disease (PD) in patients from the fisogatinib phase 1 trial, we sequenced circulating tumor DNA (ctDNA), which is minimally invasive to patients and allows for repeat sample collection. Pre-and posttreatment pairs were available from 31 of 115 total patients enrolled in the study. Baseline characteristics were representative of the total patient population ( Supplementary Table S1 ) (18) . Twenty-five patients (82%) were positive for FGF19 expression by immunohistochemistry, and 16 patients remained on treatment for at least 6 months. Overall, ctDNA analysis showed evidence of mutations in 12 genes, with 7 mutations being recurrent and elevated at progression (Supplementary Figure S1 ). Seven patients responded to fisogatinib by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, with 6 (27%) partial responses (PR) and 1 (5%) complete response ( Supplementary Table S2 ); ctDNA sequencing revealed evidence of acquired on-target resistance in 2 out of 7 cases (29%). The frequency of FGFR4 on-target resistance mutations is comparable to other drivers, such as EGFR (~50-60%) and ALK (~30-50%) in non-small-cell lung cancer (2, 3 Patient 1 was an 81-year-old Caucasian male presenting with Barcelona Clinic Liver Cancer (BCLC) stage C HCC with a nonviral alcoholic cirrhosis etiology. This patient had received 3 prior therapies, including sorafenib and 2 radiotherapy applications after disease progression on sorafenib. This patient's tumor had FGF19 overexpression without FGF19 amplification ( Fig. 1A) . Fisogatinib was given at 280 mg/day for the first 8 monthly cycles and 600 mg/day for cycle 9, resulting in a PR with a 44% reduction in tumor size after 16 weeks. At week 32, the patient experienced progressive disease (PD) and the fisogatinib dose was increased to the 600 mg recommended phase 2 dose before discontinuation of treatment.
Sequencing of ctDNA at baseline revealed that only wild-type FGFR4 was detectable before treatment with fisogatinib. By the end of treatment, mutations that corresponded to the gatekeeper (V550M and V550L) and hinge-1 (C552R) residues of FGFR4 were present ( Fig. 
1B-1C).
Patient 2 was a 64-year-old Asian male with BCLC stage C HCC arising from hepatitis B virus infection. This patient's tumor had FGF19 overexpression without FGF19 amplification at baseline ( Fig. 1D) . At the time of enrollment, he had received 1 month of sorafenib, which had been discontinued due to toxicity. This patient was given fisogatinib at 600 mg/day for 8 monthly cycles. After 16 weeks, he had stable disease with a 15% radiographic reduction in tumor size.
By week 31, the patient experienced PD and was removed from the study. ctDNA sequencing at baseline indicated the presence of wild-type FGFR4. Following treatment with fisogatinib, a mutation was detected in FGFR4 that corresponded with the gatekeeper residue V550M ( Fig.   1E-1F ).
Characterization of Fisogatinib Resistance Mutations
Fisogatinib binds specifically to FGFR4 via a covalent interaction with a unique residue, C552 in the ATP binding pocket (Supplementary Fig. S2 ). We hypothesized that mutations at residue C552 in the FGFR4 ATP binding pocket would reduce fisogatinib binding and inhibitory activity, promoting fisogatinib resistance. A crystal structure of fisogatinib with the kinase domain of FGFR4 combined with enzyme k inact measurements confirmed that the reactive acrylamide moiety of fisogatinib covalently binds with residue C552 within the ATP binding pocket of FGFR4 (19) . We hypothesized that mutations at this position would deleteriously erode fisogatinib binding and inhibitory activity. Additionally, given the complementary fit of the dichloro-dimethoxyphenyl headpiece of fisogatinib in a hydrophobic pocket of FGFR4 lined by V550, we predicted that fisogatinib binding would be vulnerable to mutations substituting residue V550 with bulkier amino acids ( Fig. 2A) To corroborate clinical findings and validate that FGFR4 mutations at these key residues arise from persistent exposure to fisogatinib, a resistance screen was conducted in vitro. Ba/F3 cells expressing the fusion protein TEL-FGFR4 were exposed to increasing concentrations of fisogatinib until clonal outgrowth. Ba/F3 clones were considered resistant if the IC 50 of fisogatinib against a clone was ≥300-fold higher than against the parental line. Fisogatinib is an ideal compound for this screen because it is a highly kinome-selective inhibitor of FGFR4 with a dissociation constant (Kd) of 5 nM that is 134-495-fold higher for FGFR4 than for other FGFRs ( Supplementary Table S3 ). Eleven unique mutations were identified across multiple concentrations of fisogatinib, the most frequent occurring in either hinge-1 or gatekeeper residues of FGFR4, as predicted. At the lowest concentration (10 nM), mutations were also identified at residues V548 and A553. The V550L, V550M, and C552R mutations, which were observed in patients treated with fisogatinib, were among the mutants identified in the resistance screen ( Fig. 2B) . IC 50 values for the antiproliferative activity of fisogatinib indicated a 300-to 30,000-fold reduction in the potency of fisogatinib against FGFR4 mutants compared with wild-type FGFR4 (Fig. 2C) . The pan-FGFR inhibitors infigratinib (NVP-BGJ398) and erdafitinib, and the multikinase inhibitors sorafenib and regorafenib were also tested against FGFR4-mutant Ba/F3 cell lines. Gatekeeper mutations significantly reduced the antiproliferative activity of NVP-BGJ398 and erdafitinib, while the weak activity of sorafenib and regorafenib on FGFR4-mediated proliferation was less affected ( Supplementary Table S4 ).
To confirm that FGFR4 hinge-1 mutations prevent covalent binding of fisogatinib, we used ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
Unbound, wild-type FGFR4 can be detected at a retention time of 7.83 minutes, while FGFR4 bound by fisogatinib can be detected at a retention time of 11.13 minutes. Fisogatinib covalently bound wild-type FGFR4 in Ba/F3 cells but failed to generate an appreciable peak after 11.13 minutes in cells harboring a representative hinge or gatekeeper mutation ( Fig. 2D) . A peak at 7.83 minutes was observed in Ba/F3 cells treated with vehicle and in all mutant lines treated with fisogatinib ( Supplementary Fig. 3A) .
UPLC-MS/MS cannot be used to quantitatively assess the impact of FGFR4 gatekeeper mutations on fisogatinib because it measures only covalent binding. Therefore, we measured the impact of fisogatinib on the enzymatic activity of the FGFR4 V550L gatekeeper mutant.
While fisogatinib was highly potent against wild-type FGFR4 (IC 50 = 4 nmol/L), it only weakly inhibited FGFR4 V550L enzymatic activity (IC 50 = 3,110 nmol/L), suggestive of impaired binding ( Supplementary Table S5 ). Given the inability of fisogatinib to covalently bind hinge-1 mutant FGFR4 or to inhibit FGFR4 V550L enzymatic activity, we next assessed the impact of FGFR4 mutations on the ability of fisogatinib to inhibit downstream signaling of FGFR4, which normally leads to ERK phosphorylation (20) . Fisogatinib markedly decreased ERK phosphorylation in Ba/F3 cells expressing wild-type FGFR4. However, fisogatinib did not affect ERK phosphorylation in those expressing FGFR4 mutations, which is consistent with the observed loss of potency against hinge-1 and gatekeeper mutants ( Fig. 2E) .
To further elucidate the mechanism of the acquired mutations identified in FGFR4, we characterized fisogatinib resistance in vivo using human HCC Hep3B cells, which have amplified FGF19 and express FGFR4 and KLB, making them highly sensitive to fisogatinib ( Supplementary Table S6 ). Mice bearing Hep3B xenograft tumors were treated with 100 mg/kg fisogatinib orally twice daily until tumors reached approximately 200 mm 3 . Fisogatinib administration was then halted until tumors regrew to approximately 700 mm 3 . This cycle was repeated 3 times, and then fisogatinib was halted for tumors to grow until day 100 or until they reached 1000 mm 3 (Fig. 2F) . Eight mice harbored tumors that grew in the presence of fisogatinib. Sequencing of isolated tumor DNA revealed that each had a missense mutation in FGFR4, with 7 having gatekeeper mutations and 1 having a hinge-1 mutation ( Supplementary   Table S7 ). Of the gatekeeper mutations observed, only V550L and V550M, which were also observed clinically, were present.
To rule out the possibility that resistance was mediated by an off-target mutation, the clinically relevant FGFR4 V550M mutation was knocked into Hep3B cells using CRISPR-Cas9 gene editing. The resulting knock-in cell line and a wild-type control (Supplementary Figure   3B ) were treated with increasing concentrations of fisogatinib. Fisogatinib potently inhibited FGFR4 wild-type but not FGFR4 V550M-mediated signal transduction (Fig. 2G) . These findings confirm that FGFR4 gatekeeper mutations are a mechanism of acquired resistance to fisogatinib.
Fisogatinib Resistant Models Retain FGF19-FGFR4 Pathway Dependency
Because FGFR4 gatekeeper mutations were identified as clinically relevant mechanisms of fisogatinib resistance, we hypothesized that an FGFR4 inhibitor that does not bind to the stage inhibitor with pan-FGFR activity, was assessed as a proof-of-concept tool to examine this principle.
A crystal structure of LY2874455 bound to the kinase domain of FGFR4 revealed that this inhibitor did not bind to the gatekeeper pocket of FGFRs and might not be affected by FGFR4 gatekeeper mutations (Fig. 3A) . LY2874455 was similarly potent against wild-type FGFR4 and FGFR4 V550L enzymatic activity, with IC 50 s of 1.0 nmol/L and 0.4 nmol/L, respectively ( Supplementary Table S8 ). To investigate how this enzymatic inhibition translates to an antiproliferative effect in vitro, fisogatinib-resistant Ba/F3 cells were treated with LY2874455 ( Supplementary Table S9 ). The antiproliferative activity of LY2874455 was equivalent to that of fisogatinib in cells expressing wild-type FGFR4 but was approximately 25to 100-fold more potent in cells expressing gatekeeper mutants as published previously (21) and was 700-to 5500-fold more potent against cells expressing hinge-1 mutants compared with fisogatinib ( Fig. 3B) . LY2874455 was also efficacious against Hep3B tumorspheres generated from CRISPR-Cas9 gene-edited Hep3B cells expressing FGFR4 V550M whereas fisogatinib was not (Supplementary Fig. S4 ). Signal transduction downstream of wild-type and mutant FGFR4 was also similarly affected by LY2874455, and this finding was mirrored with wild-type and V550L FGFR4 knock-in Hep3B cells ( Fig. 3C and 3D, Supplementary Fig. S5) .
The ability of LY2874455 to function against mutant FGFR4 was further confirmed in vivo. The pharmacokinetic properties and bioavailability profile of LY2874455 make it suitable for in vivo oral dosing. Hep3B cells from the fisogatinib-resistant mouse model harboring a V550M mutation or naïve Hep3B cells expressing wild-type FGFR4 were implanted into mice, which were treated with either LY2874455 (3 mg/kg once or twice daily) or fisogatinib (100 mg/kg twice daily). While V550M-harboring tumors were resistant to fisogatinib, their growth was significantly delayed following treatment with LY2874455. Wild-type FGFR4 Hep3B tumors were sensitive to both compounds (Fig. 3E) . These findings demonstrate that a gatekeeperagnostic inhibitor, such as LY2874455, can directly overcome resistance to fisogatinib in vitro and in vivo and that fisogatinib-resistant disease retains FGF19-FGFR4 pathway dependency.
DISCUSSION
Resistance to therapies targeting oncogenic drivers remains a significant clinical challenge (2) .
Though this resistance can occur via multiple mechanisms, the result is inevitably reactivation of signaling through pathways that facilitate cellular proliferation and survival. Given that most kinase inhibitors are small hydrophobic compounds that can rapidly outcompete ATP for their intracellular target, a common form of resistance has been on-target mutation within the kinase domain active site (22) . This form of resistance limits the duration of response for patients; however, it also highlights the oncogene dependency of a given cancer and can be used to validate oncogenic drivers. Selective targeted therapies do not currently exist for HCC, and accordingly, clinical validation of potential drivers of this disease has not yet occurred.
Here we uncovered acquired resistance mechanisms with a potent and selective inhibitor of FGFR4, fisogatinib. Fisogatinib was active in patients with HCC who had FGF19 overexpression as measured by immunohistochemistry in a Phase I study (18) . Although These mutations were validated using in vitro and in vivo screening efforts that employed clinically active doses of fisogatinib. Given that gatekeeper mutations were more common than hinge-1 mutations, we speculated that a gatekeeper-agnostic compound with FGFR4 inhibitory activity would effectively illustrate whether a fisogatinib-resistant disease remains dependent on FGF19-FGFR4 pathway activation. We found that LY2874455, which does not bind to the gatekeeper pocket of FGFR4, was active in fisogatinib-resistant in vitro and in vivo models. This observation of differential resistance in the context of consistent oncogene dependence has important implications for treatment sequencing in HCC and supports the clinical development of next-generation FGFR4 inhibitors that maintain FGFR4 selectivity while accounting for resistance mechanisms.
Together, our results corroborate studies implicating gatekeeper mutations as the primary form of resistance for FGFR family members (23) (24) (25) . In further validating a driver of HCC, we reveal that one of the most prevalent and lethal cancers is amenable to targeted therapy. 
METHODS
Kinase Selectivity Profiling
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Author Manuscript Published OnlineFirst on October 1, 2019; DOI: 10.1158/2159-8290.CD- Fisogatinib was screened at 3 μmol/L using the KINOMEscan Assay Platform (DiscoveRx, Fremont, California). Dissociation constants (K d ) for test compound-kinase interactions were calculated by measuring the amount of kinase captured on the solid support as a function of the KINOMEscan test compound concentration. The S(10) score was calculated as described by Karaman et al (26) and is reflective of the number of kinases bound by fisogatinib over the total number of wild-type kinases. The instruments were controlled by Analyst TF 1.7 (SCIEX). The intensities of the peptides and IS were determined by integration of extracted ion peak areas using MultiQuant 3.0 (SCIEX).
UPLC-MS/MS
The peptide:IS peak area ratio was used for comparison across samples. Calibration curves were prepared by plotting the peptide:IS peak area ratio vs concentration (ng/mL). The model for the calibration curves was linear with (1/x 2 ) weighting. Peptide concentrations (ng/mL) measured in the digested samples were corrected for sample workup and converted to actual protein concentrations in Ba/F3 cell pellets (ng/mg total protein).
Fisogatinib in vitro Resistance Screen
Ba/F3 cells were mutagenized using ENU and seeded in 96-well plates. Fisogatinib was applied at concentrations ranging from 10 nmol/L-3 µmol/L and incubated until the appearance of resistant clones. Genomic DNA was isolated from resistant clones and sequenced to identify mutations (Genewiz, South Plainfield, New Jersey).
Proliferation Studies
Cell lines were seeded in respective growth media and allowed to grow overnight. Each was
Author Manuscript Published OnlineFirst on October 1, 2019; DOI: 10.1158/2159-8290.CD-19-0367 treated with fisogatinib, LY2874455, NVP-BGJ398, erdafitinib, sorafenib, or regorafenib at the doses shown for 2 cell doublings. Viability was assessed using CellTiter-Glo (Promega, Madison, Wisconsin).
Immunoblotting and Antibodies
Cell lines were treated with a given compound at the indicated concentrations for 60 minutes.
Cells were pelleted and lysed as described previously (16) . Protein concentration was determined using a bicinchoninic acid assay. Western blotting was performed using lysates that were normalized to 50 μg per total protein per lane in loading buffer (Thermo Fisher Scientific, Waltham, Massachusetts). Proteins were separated using sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Thermo 
In vivo Assays
Studies were performed at Wuxi AppTec Co, Ltd. All procedures relating to animal handling, care, and treatment were performed according to the guidelines approved by the Institutional Animal Care and Use Committee of Wuxi AppTec Co following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care. Female Balb/c nude mice (Shanghai LC Laboratory Animal Co., Ltd.) were inoculated subcutaneously with Hep3B cells or their fisogatinib-resistant derivative (10×10 6 ) in 0.2 mL of phosphate-buffered saline mixed with BD Matrigel (50:50; BD Biosciences, San Jose, California). Fisogatinib was dissolved in polyethylene glycol 400; 2-hydroxypropyl-γ-cyclodextrin was then added to 20% volume.
LY2874455 was dissolved in 10% Acacia and dosed as indicated. Tumor volume was measured at least twice weekly using a digital caliper where tumor volume was determined by the following formula: V=0.5a×b 2 , where a and b are the long and short diameters of the tumor, respectively. 
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